American Parkinson Disease Association, Washington Chapter

Recent Headlines

Safety and Efficacy Study of Levodopa–Carbidopa Intestinal Gel in Levodopa-Responsive Participants with Advanced Parkinson's and Severe Motor Fluctuations
The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel over six to 12 months in people with advanced Parkinson’s disease (PD) and severe motor-fluctuations who have not had optimal response to oral levodopa-carbidopa treatment. Additional supportive evidence for efficacy will be assessed in the treatment of severe motor fluctuations, dyskinesia and mobility.
Read more

Studies of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Participants
The primary objective of these studies will be to demonstrate the superiority of levodopa-carbidopa intestinal gel over treatment with oral levodopa/ carbidopa during 12 weeks in people with advanced Parkinson’s disease (PD) and severe motor fluctuations. The study duration is four months.
Read more

Evidence Linking Agent Orange, Parkinson's, Heart Disease "Limited Or Suggestive", Report
Writers of a new report found "limited or suggestive evidence" that exposure to Agent Orange and other chemicals used in the Vietnam War is linked with an increased risk of developing ischemic heart disease and Parkinson's disease for veterans of that war.
Read more

Therapy For Parkinson's, Other Diseases, Advanced By ORNL
By miniaturizing a device that monitors the delivery of healthy cells, researchers at Department of Energy's Oak Ridge National Laboratory are developing a powerful instrument for physicians to use in treating patients with Parkinson's syndrome, brain tumors and other diseases.
Read more

Researchers Discover Possible Therapeutic Target To Slow Parkinson's Disease
University of Medicine and Dentistry of New Jersey (UMDNJ) researchers have discovered a therapeutic target that, when manipulated, may slow the progression of or halt Parkinson's disease, a debilitating neurodegenerative disorder that affects an estimated one million people in the U.S.
Read more

Teva Announces FDA Approval Received For Azilect® (Rasagiline)
Teva Pharmaceutical Industries Ltd. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for once-daily AZILECT® (rasagiline tablets) as a treatment for Parkinson's disease both as initial monotherapy in early Parkinson's disease patients and as adjunct therapy to levodopa in moderate-to-advanced stages of the disease.
Read more.

APDA Named Safeway's Charity of Choice for March, 2006
Safeway recently named the APDA as its "Charity of Choice" for March of 2006. Collection containers were placed at Safeway checkout stands in the Western region to give Safeway employees and customers a convenient way to help support the APDA with their spare change. Spare change adds up -- this effort raised $47,000! Thank you, Safeway!